Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases

Yuxin Li; Christiaan Schiepers; Ralph Lake; Simin Dadparvar; Gholam R. Berenji

doi:10.1016/j.bone.2011.09.053

Clinical utility of ¹⁸F-fluoride PET/CT in benign and malignant bone diseases

Yuxin Li
, Christiaan Schiepers
, Ralph Lake
, Simin Dadparvar
, Gholam R. Berenji

Department of Radiology

Research output: Contribution to journal › Review article › peer-review

84 Scopus citations

Abstract

¹⁸F labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT, there is renewed interest in using ¹⁸F-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that ¹⁸F fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to ^99mTc based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for ¹⁸F sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT using ¹⁸F-fluoride in both benign and malignant bone disorders.

Original language	English (US)
Pages (from-to)	128-139
Number of pages	12
Journal	Bone
Volume	50
Issue number	1
DOIs	https://doi.org/10.1016/j.bone.2011.09.053
State	Published - Jan 2012

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Physiology
Histology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bone.2011.09.053

Cite this

@article{24af6dd5b9f64ced9fe51d3d499cffe9,

title = "Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases",

abstract = "18F labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT, there is renewed interest in using 18F-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that 18F fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to 99mTc based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for 18F sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT using 18F-fluoride in both benign and malignant bone disorders.",

author = "Yuxin Li and Christiaan Schiepers and Ralph Lake and Simin Dadparvar and Berenji, \{Gholam R.\}",

year = "2012",

month = jan,

doi = "10.1016/j.bone.2011.09.053",

language = "English (US)",

volume = "50",

pages = "128--139",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases

AU - Li, Yuxin

AU - Schiepers, Christiaan

AU - Lake, Ralph

AU - Dadparvar, Simin

AU - Berenji, Gholam R.

PY - 2012/1

Y1 - 2012/1

N2 - 18F labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT, there is renewed interest in using 18F-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that 18F fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to 99mTc based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for 18F sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT using 18F-fluoride in both benign and malignant bone disorders.

AB - 18F labeled sodium fluoride is a positron-emitting, bone seeking agent with more favorable skeletal kinetics than conventional phosphate and diphosphonate compounds. With the expanding clinical usage of PET/CT, there is renewed interest in using 18F-fluoride PET/CT for imaging bone diseases. Growing evidence indicates that 18F fluoride PET/CT offers increased sensitivity, specificity, and diagnostic accuracy in evaluating metastatic bone disease compared to 99mTc based bone scintigraphy. National Oncologic PET Registry (NOPR) has expanded coverage for 18F sodium fluoride PET scans since February 2011 for the evaluation of osseous metastatic disease. In this article, we reviewed the pharmacological characteristics of sodium fluoride, as well as the clinical utility of PET/CT using 18F-fluoride in both benign and malignant bone disorders.

UR - https://www.scopus.com/pages/publications/80155183580

UR - https://www.scopus.com/pages/publications/80155183580#tab=citedBy

U2 - 10.1016/j.bone.2011.09.053

DO - 10.1016/j.bone.2011.09.053

M3 - Review article

C2 - 22001678

AN - SCOPUS:80155183580

SN - 8756-3282

VL - 50

SP - 128

EP - 139

JO - Bone

JF - Bone

IS - 1

ER -